Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
CTMX Cytomx Therapeutics, Inc. - 8-K
Accession
0001193125-25-2695332.029.01
Item 2.02 - Results of Operations and Financial Condition
Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.
Item 9.01 - Financial Statements and Exhibits
59 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished as part of this report. Exhibit No. Description 99.1 Press release titled "CytomX Therapeutics Announces Third Quarter of 2025 Financial Results and Provides Business Update" issued by CytomX Therapeutics, Inc. on November 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)